Properties
Description
TAK-220 specifically binds to chemokine receptors. This binding blocks the receptors and prevents the corresponding chemokines from exerting their effects on immune cells, leading to reduced chemotaxis and cell activation. It targets HIV-1 (CTV), HIV-1 (CTV), HIV-1 (HHA), HIV-1 (HHA), HIV-1 (HKW), HIV-1 (HKW), HIV-1 (HNK), HIV-1 (HNK), HIV-1 (HTN), HIV-1 (HTN), HIV-1 (KK).
Molecular Formula
C31H41ClN4O3
Targets
HIV-1 (CTV): 0.72 nM (EC50, in PBMCs); HIV-1 (CTV): 5 nM (EC90, in PBMCs); HIV-1 (HHA): 0.55 nM (EC50, in PBMCs); HIV-1 (HHA): 4 nM (EC90, in PBMCs); HIV-1 (HKW): 1.7 nM (EC50, in PBMCs); HIV-1 (HKW): 12 nM (EC90, in PBMCs); HIV-1 (HNK): 1.7 nM (EC50, in PBMCs); HIV-1 (HNK): 28 nM (EC90, in PBMCs); HIV-1 (HTN): 0.93 nM (EC50, in PBMCs); HIV-1 (HTN): 15 nM (EC90, in PBMCs); HIV-1 (KK): 1.2 nM (EC50, in PBMCs)
Identity
Confirmed by NMR/HPLC/MS.
Applications
TAK-220 is a CCR inhibitor studied for its effects on pathways involved in immune response and potential therapeutic applications.
